Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Pamidronate reduces bone loss after allogeneic stem cell transplantation.
Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling PR. Grigg AP, et al. J Clin Endocrinol Metab. 2006 Oct;91(10):3835-43. doi: 10.1210/jc.2006-0684. Epub 2006 Jul 11. J Clin Endocrinol Metab. 2006. PMID: 16835281 Clinical Trial.
BACKGROUND: Rapid bone loss occurs from the proximal femur after allogeneic stem cell transplantation (alloSCT). ...Benefits were restricted to patients receiving an average daily prednisolone dose greater than 10 mg and cyclosporin thera …
BACKGROUND: Rapid bone loss occurs from the proximal femur after allogeneic stem cell transplantation …
Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate.
Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Välimäki MJ. Kananen K, et al. J Clin Endocrinol Metab. 2005 Jul;90(7):3877-85. doi: 10.1210/jc.2004-2161. Epub 2005 Mar 29. J Clin Endocrinol Metab. 2005. PMID: 15797959 Clinical Trial.
CONTEXT: In controlled studies, bisphosphonates have been used to prevent bone loss after solid organ transplantations but not in conjunction with stem cell transplantation (SCT). ...CONCLUSIONS: The recipients of allogeneic SCT receiving …
CONTEXT: In controlled studies, bisphosphonates have been used to prevent bone loss after solid organ transplantations but not …
Bone loss and its management in long-term survivors from allogeneic stem cell transplantation.
Tauchmanovà L, Colao A, Lombardi G, Rotoli B, Selleri C. Tauchmanovà L, et al. J Clin Endocrinol Metab. 2007 Dec;92(12):4536-45. doi: 10.1210/jc.2006-2870. Epub 2007 Oct 2. J Clin Endocrinol Metab. 2007. PMID: 17911175 Review.
CONTEXT: Recently, great efforts have been made to understand the pathogenesis of bone loss after allogeneic stem cell transplant (allo-SCT) and possible treatments. EVIDENCE ACQUISITION: A literature search of the MEDLINE database was performed …
CONTEXT: Recently, great efforts have been made to understand the pathogenesis of bone loss after allogeneic stem …